Rome, Nov 16. (Adnkronos) – Médecins Sans Frontières (MSF) warns that the shortage of diphtheria antitoxin (DAT), the essential drug for treating diphtheria, combined with low vaccination coverage, is fueling the transmission of the disease and compromising efforts to contain the epidemic in northern Nigeria, exposing thousands of children to the risk of contracting a severe illness and death. To save lives and help contain the epidemic, MSF urges federal and state authorities, donors, and international partners to urgently ensure the availability of diphtheria antitoxin stocks, vaccines, and other essential medicines, as well as to ensure their timely clearance at ports of entry and rapid distribution in affected areas in northern Nigeria.
“The global shortage of diphtheria antitoxin is becoming a matter of life or death. Our stocks are dangerously low, and we risk not being able to treat children and save lives as the epidemic continues,” says David Kizito, MSF medical coordinator in Nigeria. “Diphtheria is a preventable disease, yet children continue to arrive at health facilities with life-threatening complications because they are not fully vaccinated or cannot access care in time.”
Diphtheria antitoxin is the only specific treatment capable of neutralizing the toxin produced by the disease. It is included in the WHO’s list of essential medicines, but despite its importance, global availability remains dangerously erratic. Diphtheria antitoxin is most effective if administered within 48 hours of symptom onset, but MSF teams repeatedly face situations where supplies are insufficient or unavailable, compromising patients’ clinical outcomes and forcing medical teams to ration treatment.
Nigeria has been facing a severe diphtheria epidemic since late 2022. Since the beginning of the epidemic, the overall toll has exceeded 41,000 suspected cases, over 24,000 confirmed infections, and more than 1,260 deaths nationwide. Northern states, including Bauchi, Borno, Kaduna, Katsina, Kano, Plateau, Sokoto, and Zamfara, remain particularly affected, and many areas have seen recent peaks in cases. In 2026 alone, as of August 9, Nigeria had recorded 12,977 suspected cases, 10,476 confirmed infections, and 406 deaths.
MSF has supported state health authorities through patient care, infection prevention and control, surveillance, community engagement, health promotion, referral and transfer systems to other facilities, support for vaccination campaigns, and the provision of medical supplies. In the states of Kano, Sokoto, and Zamfara, MSF teams are treating patients and providing support to isolation and treatment facilities, while further support is provided in the states of Bauchi, Katsina, and Kebbi.
This year, since the start of epidemic response activities, MSF has treated over 9,000 diphtheria patients through care provided both in health facilities and at the community level, and has scaled up emergency activities in the most affected areas. In collaboration with the Kano State Ministry of Health, MSF also supported a two-phase vaccination campaign in April and June, administering over 835,000 vaccine doses to children across Kano State.
Following the declaration of an epidemic in Zamfara state in September, MSF-supported facilities in Gusau recorded over 671 admissions in one month starting October 6. Most of those admitted were children, and 4 out of 5 patients had not been vaccinated. In Sokoto state, MSF also supported two vaccination cycles between February and April, reaching 49,018 children under 15 years of age.
Routine vaccination remains crucial for preventing diphtheria, but coverage in northern Nigeria, particularly in rural areas, remains low. In Zamfara state, only 25,000 of the 90,000 vaccine doses needed for a reactive campaign were provided, leaving approximately 3 out of 4 children uncovered. MSF is collaborating with government health authorities to secure additional doses and implement a large-scale vaccination campaign.
“We were very worried when our first child fell ill because at the time we knew very little about diphtheria,” says Shafa’atu, a mother whose 3 children were treated for diphtheria at the MSF-supported hospital in Sokoto. “My son struggled to eat, and every time he ate, he would vomit. Diphtheria is a dangerous disease.” A consistent and long-term investment in routine vaccination is crucial for building community immunity and preventing future epidemics. At the same time, global manufacturers and health partners must urgently scale up diphtheria antitoxin production and ensure a reliable supply to meet essential therapeutic needs in Nigeria and other countries experiencing an increase in cases.